bioAffinity Technologies, Inc.
BIAF
$3.84
-$0.16-3.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -34.18% | -27.66% | 4.99% | 78.40% | 269.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.18% | -27.66% | 4.99% | 78.40% | 269.68% |
| Cost of Revenue | -29.36% | -19.67% | 14.11% | 74.34% | 243.70% |
| Gross Profit | -42.72% | -42.47% | -11.60% | 86.67% | 326.79% |
| SG&A Expenses | -0.30% | 6.06% | 11.86% | 30.42% | 46.43% |
| Depreciation & Amortization | -16.63% | -10.99% | 12.94% | 61.71% | 142.53% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.63% | -3.15% | 11.00% | 38.70% | 74.34% |
| Operating Income | -18.08% | -24.35% | -16.07% | -15.25% | -12.29% |
| Income Before Tax | -64.66% | -74.31% | -33.55% | -16.38% | -14.05% |
| Income Tax Expenses | 276.92% | 192.14% | 194.16% | 29.46% | -44.29% |
| Earnings from Continuing Operations | -64.94% | -74.51% | -33.80% | -16.40% | -13.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.94% | -74.51% | -33.80% | -16.40% | -13.89% |
| EBIT | -18.08% | -24.35% | -16.07% | -15.25% | -12.29% |
| EBITDA | -20.60% | -27.09% | -16.26% | -11.71% | -8.08% |
| EPS Basic | 31.02% | 13.49% | 22.88% | 22.70% | 17.54% |
| Normalized Basic EPS | 31.17% | 13.58% | 22.98% | 22.71% | 17.43% |
| EPS Diluted | 31.02% | 13.49% | 22.88% | 22.70% | 17.54% |
| Normalized Diluted EPS | 31.17% | 13.58% | 22.98% | 22.71% | 17.43% |
| Average Basic Shares Outstanding | 325.63% | 102.36% | 71.51% | 50.35% | 38.60% |
| Average Diluted Shares Outstanding | 325.63% | 102.36% | 71.51% | 50.35% | 38.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |